More frequent dosing for refractory nAMD?

A closer look at biweekly anti-VEGF dosing for chronic disease that doesn’t respond completely to standard monthly dosing.

New revelations for nAMD, CSC treatments and ILM utility

Trial readouts on improving treatment durability, a potential new therapy for central serous chorioretinopathy and adding to the debate of RRD repair.

Gene therapy in AMD: Promises and challenges

Gene therapy could offer long-term stable control and prevent non-compliance, but the long-term effectiveness remains to be seen.

Gene therapy and editing for the retina: A primer

A look at advances in gene replacement therapy, gene delivery and CRISPR technology.

Is drier better in neovascular AMD?

It may depend on the location of the fluid. A quick look at HARBOR post-hoc results.

Pipeline Report: Despite major approvals, the queue gets longer

Treatments for exudative disease were notable for four significant exits from our listing and seven new entries this year.

Pipeline Report: The path to GA treatment: What’s hot, what’s not

A review of past trials that disappointed and current trials that are showing promise as potential treatments.

First results of gene and cell therapies for nAMD, RP, plus ...

Findings on predictors of endophthalmitis, widefield OCT-A vs. FA and microsecond pulsing laser make five worthy takeaways.

Downside of finger flicks, upside of abicipar changes

These findings and three other presentations on SRF/IRF, stable CST and oral therapy give new insights into nAMD.

20 milestones ahead in AMD, DME meds

A look at chemical and biologic agents queued this year or next for key steps toward commercialization.

Targeting Unmet Needs in nAMD Treatment

A look at longer-acting anti-VEGF agents, sustained-release delivery, gene therapy and novel molecules in development.

The Choroid in AMD: A Critical Point of Failure?

Advancements in imaging and new computational models are improving our understanding of choroidal failure.

The ‘Switch’ and Macular Atrophy in nAMD

New insights into how frequent, long-term anti-VEGF injections and a change in medication impact RPE loss.

Answers to the Three Big Questions of Long-Term Treatment of Wet AMD

Anti-VEGF agents have forced us to choose an agent and regimen, and learn when enough is enough.

Retina Report from ARVO 2016

A closer look at five abstracts on VMT, DME, AMD, OCT and gene therapy.

TAE for Wet AMD: Practical Tips from the Pros

A conversation on the nuances of implementing treat and extend.

Subclinical MNV: Do We Watch or Treat?

Now that we have OCT-A, we can no longer ignore macular neovascularization in non-exudative AMD.

Big Data and AMD Progression

Gathering and analyzing imaging biomarkers from SD-OCT along with other inputs can aid in tracking patients.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.